Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous γδT Cells in Relapsed/Refractory NHL, CLL, and PTCL
NCT04028440Phase 1Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous γδT cells in B-cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL) and peripheral T-cell lymphoma (PTCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Number of Participants with Severe/Adverse Events at 15 months and Overall Response Rate at 28 days. Status: unknown.
02
Drugs
autologous γδT cells
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)chronic lymphocytic leukemia (CLL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04028440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04028440.